| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.4 | 3.3 | 2.7 |
| Total income | 1.4 | 3.3 | 2.8 |
| Profit before exceptional items & tax | 0.1 | 0.7 | -0.2 |
| Profit before tax | 0.1 | 0.7 | -0.2 |
| Net profit | 0.1 | 0.7 | -0.2 |
| Operating margin | 7.1% | 21.2% | -7.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -85.70% |
|---|---|
| Revenue, year on year | -48.10% |
BSE results filing, NSE: NORRIS. Figures extracted from the filing.
Norris Medicines Ltd: key numbers
- Share price
- ₹18.70
- Market cap
- ₹18.70 Cr
- Revenue (annual)
- ₹8.13 Cr
- Net profit (annual)
- ₹-0.28 Cr
- P/E (TTM)
- -51.0×Sector 50.4×
- Promoter holding
- 34.01%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Norris Medicines Ltd
All →Norris Medicines Annual Report
Norris Medicines Limited has filed its 35th Annual Report for the financial year 2025-26, including the notice of its upcoming Annual General Meeting.
Norris Medicines Annual General Meeting
Norris Medicines approved the Directors' Report, Annual Report, and convening of the 35th Annual General Meeting for September 29, 2026.
Norris Medicines Q1 FY27 Results: Net Loss of ₹0.4 Cr, Loss Widens
Norris Medicines Ltd reported revenue from operations of ₹0.9 Cr (-40.0% YoY) and a net loss of ₹0.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.4 Cr